Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction

• DOI: 10.1161/circulationaha.119.044366
• Publication Date: 2020-03-31T09:00:11Z
• Authors: Peter Marstrand; Larry Han; Sharlene M. Day; Iacopo Olivotto; Euan A. Ashley; Michelle Michels; Alexandre C. Pereira; Samuel G. Wittekind; Adam Helms; Sara Saberi; Daniel Jacoby; James S. Ware; Steven D. Colan; Christopher Semsa...; Jodie Ingles; Neal K. Lakdawala; Carolyn Y. Ho
• Keywords: Adult; Male; 610; heart failure; hypertrophic; cardiomyopathy, hypertrophic; genetics; heart failure; prognosis; ventricular dysfunction; 1117 Public Health and Health Services; Ventricular Dysfunction, Left; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Original Research Articles; Humans; genetics; Registries; 10. No inequality; cardiomyopathy, hypertrophic; 1102 Cardiorespiratory Medicine and Haematology; SHaRe Investigators; 2. Zero hunger; Incidence; ventricular dysfunction; 1103 Clinical Sciences; Cardiomyopathy, Hypertrophic; Middle Aged; Prognosis; 3. Good health; Cardiovascular System & Hematology; Female; prognosis; cardiomyopathy; EMC COEUR-09

The term "end stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when ejection fraction is <50%. prognosis of HCM-LVSD reportedly poor, but because its relative rarity, the natural history remains incompletely characterized.